Figure 1.

Overexpression of JC15 leads to enhanced chemosensitivity. (a) Relative viability of cells variably expressing JC15 or JC15_V133W were either left untreated or treated with cisplatin (+Cpl) and measured using MTT assay. Data are represented as mean±S.E.M. n=8, *P (two tailed) <0.0001, **P (two tailed) <0.001. (b and c) Cisplatin-treated cells with altered levels of JC15 or JC15_V133W mutant were dual stained with AnnexinV–AlexaFlour 488/propidium iodide (PI) (b) or AnnexinV–AlexaFlour 488/MitoTracker Red CMXRos (c). Bars represent mean±S.E.M. n=3, *P (two tailed) <0.0001, **P (two tailed) <0.001; UnT, untreated untransfected cells; T, untransfected cells treated with cisplatin. (d) Fold caspase 3/7 activity of cells with altered wild-type or mutant JC15 expression over untransfected cells represented as mean±S.E.M. n=3, *P (two tailed) <0.0001, **P (two tailed) <0.001; NT, non-targeting siRNA control; UT, cisplatin-treated untransfected cells. (e and f) Isolated mitochondria overexpressing JC15 and JC15_V133W were induced to swell in the absence (e) or presence (f) of 1 nM cyclosporin (CsA) and represented as mean±S.E.M. n=3, P<0.0001 with reference to UT